Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0038002 (
splenomegaly
)
9,873
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The bioactive lipid sphingosine-1-phosphate (S1P) is emerging as an important mediator of immune and inflammatory responses. S1P formation is catalyzed by sphingosine kinase (SK), of which the
SK1
isoenzyme is activated by tumor necrosis alpha (TNF-alpha).
SK1
has been shown to be required for mediating TNF-alpha inflammatory responses in cells, including induction of cyclooxygenase 2 (COX-2). Because TNF-alpha and COX-2 are increased in patients with inflammatory bowel disease (IBD), we investigated the role of
SK1
in a murine model of colitis.
SK1
(-/-) mice treated with dextran sulfate sodium (DSS) had significantly less blood loss, weight loss, colon shortening, colon histological damage, and
splenomegaly
than did wild-type (WT) mice. In addition,
SK1
(-/-) mice had no systemic inflammatory response. Moreover, WT but not
SK1
(-/-) mice treated with dextran sulfate sodium had significant increases in blood S1P levels, colon
SK1
message and activity, and colon neutrophilic infiltrate. Unlike WT mice,
SK1
(-/-) mice failed to show colonic COX-2 induction despite an exaggerated TNF-alpha response; thus implicating for the first time
SK1
in TNF-alpha-mediated COX-2 induction in vivo. Inhibition of
SK1
may prove to be a valuable therapeutic target by inhibiting systemic and local inflammation in IBD.
...
PMID:A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. 1881 59